In short
Clinical trials are studying ZILEBESIRAN in people with hypertension that is not well controlled and who also have established cardiovascular disease or high cardiovascular risk. These trials aim to see whether it can lower major heart and blood vessel events, including death, heart attack, stroke, and heart failure events.
Key points
- ZILEBESIRAN is being studied in a large Phase 3 trial in people with hypertension that is not adequately controlled. The trial also includes people with established cardiovascular disease or high cardiovascular risk. Researchers want to know whether ZILEBESIRAN can lower the chance of major cardiovascular events. The main outcomes include cardiovascular death, nonfatal heart attack, nonfatal stroke, and heart failure events. This is an interventional study with more than 11,000 planned participants. The trial is authorised and compares ZILEBESIRAN with placebo.
Trial overview
The main trial in the source data is ZENITH, a Phase 3 study of ZILEBESIRAN in people with hypertension that is not adequately controlled and who have either established cardiovascular disease or high cardiovascular risk.
This is an interventional study, which means researchers give a study treatment and compare outcomes between groups.
Who can participate
The trial is designed for people with hypertension, which means high blood pressure, when it is not well controlled.
Participants must also have either established cardiovascular disease or high cardiovascular risk, meaning they already have heart or blood vessel disease, or they have a higher chance of having one in the future.
Study design and phase
The study is in Phase 3, which is a late stage of testing done in a large group of people to see how well a treatment works.
The planned enrollment is 11,038 people, showing that this is a large trial meant to give strong evidence about the study treatment.
The trial is authorised, which means it has been approved to move forward in the research process.
What is being measured
The main endpoint, or main result, is the time to first occurrence of a composite endpoint.
A composite endpoint combines several serious health events into one main measure. In this trial, those events are cardiovascular death, nonfatal heart attack, nonfatal stroke, and heart failure events such as a hospital stay for heart failure or an urgent heart failure visit.
The brief summary says the study is testing whether ZILEBESIRAN, compared with placebo, reduces the risk of these major cardiovascular events.
Why this trial matters
People with uncontrolled hypertension and cardiovascular disease are at higher risk for serious heart and blood vessel problems.
This trial is important because it focuses on whether a study treatment can reduce major events that affect survival and quality of life, not just blood pressure numbers.